| Splenic Lymphoma studied in …STUDIED_INderived166 of 166show fewer |
|---|
| → studied in | NCT07583810Phase 2 · recruiting Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07055477Phase 1 · recruiting A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03113500Phase 2 · active not recruiting Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03198026Phase 2 · active not recruiting Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas · condition mapped CURATED_BROADER · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07759661not yet recruiting Innovative 3D Preclinical Models for Mature B-cell Malignancies to Advance Personalized Immuno and Combination Therapies · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01479842Phase 1 · active not recruiting Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05735834Phase 3 · active not recruiting Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05377827Phase 1 · suspended Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07638722Phase 2 · not yet recruiting Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment · condition mapped CURATED_BROADER · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07691450Phase 1 · not yet recruiting Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma · condition mapped CURATED_BROADER · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01815749Phase 1 · active not recruiting Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02332980Phase 2 · completed Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas · condition mapped CURATED_BROADER · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05475925Phase 1/Phase 2 · recruiting A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01787409NA · active not recruiting Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02232516Phase 2 · completed Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03598998Phase 1/Phase 2 · active not recruiting Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas · condition mapped CURATED_BROADER · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05978141recruiting A Registry for People With T-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06859008Phase 1 · recruiting Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01384513Phase 2 · completed A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03697512Phase 2 · active not recruiting MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02213913Phase 1/Phase 2 · completed Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05544019Phase 1 · recruiting Study of SGR-1505 in Mature B-Cell Neoplasms · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01199562active not recruiting Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04223765Phase 1 · recruiting Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06796998Phase 2 · recruiting Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01804166Phase 4 · completed A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02168140Phase 1 · completed CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01769222Phase 1 · terminated Ipilimumab and Local Radiation for Selected Solid Tumors · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02561273Phase 1/Phase 2 · completed Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01523223Phase 1 · completed Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04795869Phase 2 · withdrawn Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma · condition mapped CURATED_BROADER · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01336933Phase 2 · completed Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01044745Phase 2 · terminated Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04639843Phase 1 · withdrawn Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04635683Phase 1 · withdrawn Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma · condition mapped CURATED_BROADER · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02049541Phase 1 · completed Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04836832Phase 1 · withdrawn Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01261247Phase 2 · completed Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01805037Phase 1/Phase 2 · terminated Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02945319completed Integrated Molecular and Clinical Profiling to Optimize Outcome Prediction in Splenic Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02037256NA · completed Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00536601NA · completed High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01678443Phase 1 · terminated Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01258998Phase 2 · completed Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01075321Phase 1/Phase 2 · completed Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03075553Phase 2 · terminated Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00082888Phase 2 · completed Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00918333Phase 1/Phase 2 · completed Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02533700Phase 2 · unknown CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00040846Phase 2 · completed Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00089011Phase 2 · completed Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00006251Phase 1/Phase 2 · completed Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00014235NA · completed Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00078858Phase 1/Phase 2 · completed Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01239875early Phase 1 · completed Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00003196NA · completed Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01326702Phase 1/Phase 2 · completed Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02254772Phase 1/Phase 2 · completed A Phase I/II Study of Intratumoral Injection of SD-101 · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02087878withdrawn A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel Disease, Who Have Been Treated With Adalimumab and Who Developed Hepatosplenic T-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02652715NA · completed Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00856388NA · completed Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01529827Phase 2 · completed Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00005799NA · completed Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01839916Phase 2 · completed Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01159067Phase 2 · terminated Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01408043NA · terminated Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00711828Phase 2 · completed Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01093586Phase 2 · completed Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01590732Phase 1 · completed Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma · condition mapped CURATED_BROADER · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01273766Phase 2 · completed Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00012298Phase 1/Phase 2 · terminated Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01789255Phase 2 · completed Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01484015Phase 1 · completed Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02168907Phase 1 · terminated CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00119392Phase 2 · completed Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01812005Phase 2 · terminated Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01129193Phase 1 · completed AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01567709Phase 1 · completed Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01719835Phase 2 · unknown CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study · condition mapped ALIAS · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00867529Phase 2 · completed Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01746992Phase 4 · unknown CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01701232Phase 3 · completed Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01682044Phase 2 · completed Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01254578Phase 1 · completed Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00073918Phase 2 · completed Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01720758completed Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01419795Phase 2 · terminated Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00072514Phase 2 · completed Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01076270NA · terminated Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00118352Phase 2 · completed Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00088881Phase 2 · terminated Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00601718Phase 1/Phase 2 · completed Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00112593NA · completed Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01110135Phase 2 · completed Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00795769Phase 2 · completed Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00244855Phase 2 · completed Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01427881Phase 2 · completed Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00049504Phase 2 · completed Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00408681NA · completed Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02742727Phase 1/Phase 2 · unknown CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02281279Phase 1/Phase 2 · withdrawn Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00112723Phase 1/Phase 2 · terminated Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01652014Phase 2 · withdrawn Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01466881Phase 2 · completed Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00438880Phase 1/Phase 2 · completed Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01748721Phase 1 · completed MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01045928Phase 1 · terminated Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00131937Phase 2 · completed Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02109224Phase 1 · terminated Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00566332Phase 3 · completed Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01658319Phase 1 · completed Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01959477early Phase 1 · completed Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00608361Phase 1 · completed Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00720135Phase 1 · completed Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01769911NA · withdrawn Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00003210Phase 2 · completed Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00343798Phase 1 · completed A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00082784Phase 1 · completed Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01158274Phase 1 · completed RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00288067Phase 1/Phase 2 · terminated Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00275080Phase 1 · completed Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00110071Phase 1 · completed Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00621452Phase 1 · completed Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00901147Phase 2 · completed Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00089076Phase 1/Phase 2 · terminated MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00054639Phase 2 · completed Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00290472Phase 2 · completed CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00933985Phase 1 · terminated Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01231919Phase 1 · completed MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01233921NA · completed Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00890747Phase 1 · completed Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00101205Phase 1 · terminated Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00499811Phase 1 · completed Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00458731Phase 1 · completed Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00769288Phase 1 · completed FAU in Treating Patients With Advanced Solid Tumors or Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00019708Phase 1 · terminated Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01129180Phase 1 · completed Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00731536completed Observational Study on the Occurrence of Hepatosplenic T-cell Lymphoma in Patients of Netherlands · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00068315Phase 1 · completed Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00293345Phase 1 · completed 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00026182Phase 2 · completed Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00010192Phase 1 · completed Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01238146Phase 1/Phase 2 · withdrawn Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00017472Phase 1 · completed Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00058227Phase 1 · completed Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00103272Phase 1 · terminated 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00054483Phase 1 · completed Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00354185Phase 1 · terminated PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00348985Phase 1 · completed PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00004241Phase 1 · completed 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00025415Phase 1 · completed Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00005786NA · terminated Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00060112Phase 1 · terminated Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00089271Phase 1 · completed 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00003970Phase 1 · completed Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00077155Phase 1 · completed Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00098891Phase 1 · completed MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00005950Phase 2 · terminated 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00101244Phase 1 · terminated SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00058305Phase 2 · completed Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00891072Phase 1 · completed Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00118170Phase 1 · completed Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01558778NA · withdrawn Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00799461Phase 3 · completed Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01116154Phase 1 · terminated Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01177371Phase 2 · completed High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |